Check out what happened at our last CDx event
Discover & Validate Novel Predictive Biomarkers
Improve Your Selection of Patient Responders
Effectively Deliver Diagnostic-Enabled Therapies to Market
As emerging technology, such as liquid biopsies, generate novel biomarker signatures that are demonstrating their predictive power, discover the very latest preclinical and clinical data proving their clinical utility in responder selection and outcome monitoring. Within oncology, competition is fierce for specific patient populations and in non-oncology indications (such as cardiovascular, CNS, autoimmune and rare diseases) the role of biomarker-based diagnostics are starting to prove their value.
World CDx Boston 2017 will also showcase industry-defining discussions on the strategic challenges facing the real world application of precision medicines and companion diagnostics to specific patients in need. Uncover solutions to key challenges including regulatory approval, pricing and reimbursement coverage, health economics behind market access hurdles and global commercialization & adoption.
Discover why, how and when to adopt a CDx strategy early on in your drug development and ensure collaboration and communication between all stakeholders.
We are currently building the agenda and speaker faculty for this years meeting. To stay in the loop and be the first to receive the 2017 agenda, please register your interest here.
Here’s what World CDx Boston 2016 Attendees had to say:
“The talks regarding the utility of a diagnostic to select patients for ImmunoOncology trials were very informative and timely, given the fast moving pace of this field.”
S. Pirie-Shepherd, Director, Pfizer
“Excellent conference for people in developing companion/complementary diagnostics for new therapeutics!”
T. Chen, Abcam plc
“I met people whom I likely would never have met if not for World CDx.”
B. Spencer, CEO, Blondin Bioscience, L